Loading...
•
Jun 30, 2021
Kodiak Sciences Q2 2021 Earnings Report
Reported business highlights and financial results for the second quarter ended June 30, 2021.
Key Takeaways
Kodiak Sciences reported a net loss of $55.9 million for the second quarter of 2021, with $880.9 million in cash and cash equivalents. The company is advancing its KSI-301 clinical program, including enrollment in Phase 3 studies for wet AMD, RVO, and DME.
Continued strong execution across clinical, regulatory and pipeline objectives in Q2 2021.
DAZZLE study continues follow-up phase with one-year primary endpoint visits.
BEACON study is nearly two-thirds enrolled, GLEAM and GLIMMER enrollment continues on pace.
First patients enrolled in DAYLIGHT study in June 2021.
Kodiak Sciences
Kodiak Sciences
Forward Guidance
Kodiak Sciences anticipates several upcoming events and milestones, including initiating the GLOW study, completing patient enrollment in BEACON, GLEAM, GLIMMER, and DAYLIGHT studies, completing the DAZZLE study, and announcing topline data for DAZZLE in Q1 2022.
Positive Outlook
- Initiate pivotal Phase 3 randomized study of every 24-week KSI-301 in non-proliferative diabetic retinopathy patients (the GLOW study)
- Complete patient enrollment in Retinal Vein Occlusion (BEACON), Diabetic Macular Edema (GLEAM and GLIMMER) and wet AMD (DAYLIGHT) pivotal clinical studies
- Complete wet AMD DAZZLE pivotal clinical study last patient last visit for primary endpoint
- Announce topline data for DAZZLE expected in the first quarter of 2022